396 related articles for article (PubMed ID: 27860138)
41. Simulation program for estimating statistical power of Cox's proportional hazards model assuming no specific distribution for the survival time.
Akazawa K; Nakamura T; Moriguchi S; Shimada M; Nose Y
Comput Methods Programs Biomed; 1991 Jul; 35(3):203-12. PubMed ID: 1935013
[TBL] [Abstract][Full Text] [Related]
42. Sample size calculation for studies with grouped survival data.
Li Z; Wang X; Wu Y; Owzar K
Stat Med; 2018 Nov; 37(27):3904-3917. PubMed ID: 29888484
[TBL] [Abstract][Full Text] [Related]
43. Subgroup detection and sample size calculation with proportional hazards regression for survival data.
Kang S; Lu W; Song R
Stat Med; 2017 Dec; 36(29):4646-4659. PubMed ID: 28791726
[TBL] [Abstract][Full Text] [Related]
44. Properties of the weighted log-rank test in the design of confirmatory studies with delayed effects.
Jiménez JL; Stalbovskaya V; Jones B
Pharm Stat; 2019 May; 18(3):287-303. PubMed ID: 30592138
[TBL] [Abstract][Full Text] [Related]
45. Three-component cure rate model for nonproportional hazards alternative in the design of randomized clinical trials.
Kim HT; Gray R
Clin Trials; 2012 Apr; 9(2):155-63. PubMed ID: 22353928
[TBL] [Abstract][Full Text] [Related]
46. Adaptive designs for the one-sample log-rank test.
Schmidt R; Faldum A; Kwiecien R
Biometrics; 2018 Jun; 74(2):529-537. PubMed ID: 28940387
[TBL] [Abstract][Full Text] [Related]
47. The efficiency of a weighed log-rank test under a percent error misspecification model for the log hazard ratio.
Zucker DM
Biometrics; 1992 Sep; 48(3):893-9. PubMed ID: 1420846
[TBL] [Abstract][Full Text] [Related]
48. Some design issues of strata-matched non-randomized studies with survival outcomes.
Mazumdar M; Tu D; Zhou XK
Stat Med; 2006 Dec; 25(23):3949-59. PubMed ID: 16596571
[TBL] [Abstract][Full Text] [Related]
49. The Inverse Log-Rank Test: A Versatile Procedure for Late Separating Survival Curves.
Efird JT
Int J Environ Res Public Health; 2023 Dec; 20(24):. PubMed ID: 38131716
[TBL] [Abstract][Full Text] [Related]
50. Sample size calculation for the combination test under nonproportional hazards.
Cheng H; He J
Biom J; 2023 Apr; 65(4):e2100403. PubMed ID: 36789566
[TBL] [Abstract][Full Text] [Related]
51. Group sequential designs for cancer immunotherapy trial with delayed treatment effect.
Wu J; Li Y; Zhu L
J Biopharm Stat; 2024 Jan; 34(1):1-15. PubMed ID: 36740768
[TBL] [Abstract][Full Text] [Related]
52. Sample size calculation for the weighted rank statistics with paired survival data.
Jung SH
Stat Med; 2008 Jul; 27(17):3350-65. PubMed ID: 18205148
[TBL] [Abstract][Full Text] [Related]
53. Designing therapeutic cancer vaccine trials with delayed treatment effect.
Xu Z; Zhen B; Park Y; Zhu B
Stat Med; 2017 Feb; 36(4):592-605. PubMed ID: 27807870
[TBL] [Abstract][Full Text] [Related]
54. An approach to trial design and analysis in the era of non-proportional hazards of the treatment effect.
Royston P; Parmar MK
Trials; 2014 Aug; 15():314. PubMed ID: 25098243
[TBL] [Abstract][Full Text] [Related]
55. Introducing a new estimator and test for the weighted all-cause hazard ratio.
Ozga AK; Rauch G
BMC Med Res Methodol; 2019 Jun; 19(1):118. PubMed ID: 31185922
[TBL] [Abstract][Full Text] [Related]
56. Mixture cure model with random effects for clustered interval-censored survival data.
Xiang L; Ma X; Yau KK
Stat Med; 2011 Apr; 30(9):995-1006. PubMed ID: 21472759
[TBL] [Abstract][Full Text] [Related]
57. Methods for non-proportional hazards in clinical trials: A systematic review.
Bardo M; Huber C; Benda N; Brugger J; Fellinger T; Galaune V; Heinz J; Heinzl H; Hooker AC; Klinglmüller F; König F; Mathes T; Mittlböck M; Posch M; Ristl R; Friede T
Stat Methods Med Res; 2024 Jun; 33(6):1069-1092. PubMed ID: 38592333
[TBL] [Abstract][Full Text] [Related]
58. A robust approach to sample size calculation in cancer immunotherapy trials with delayed treatment effect.
Ye T; Yu M
Biometrics; 2018 Dec; 74(4):1292-1300. PubMed ID: 29992543
[TBL] [Abstract][Full Text] [Related]
59. Sample size calculation for the one-sample log-rank test.
Schmidt R; Kwiecien R; Faldum A; Berthold F; Hero B; Ligges S
Stat Med; 2015 Mar; 34(6):1031-40. PubMed ID: 25500942
[TBL] [Abstract][Full Text] [Related]
60. Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials: A Systematic Review and Meta-analysis.
Mukhopadhyay P; Ye J; Anderson KM; Roychoudhury S; Rubin EH; Halabi S; Chappell RJ
JAMA Oncol; 2022 Sep; 8(9):1294-1300. PubMed ID: 35862037
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
